On this page
Weigh yourself weekly, measure your waist weekly, test your grip strength monthly, and let one fixed waistband tell you the truth slowly.
The scale still matters. But during titration, while your dose is still going up, it mostly reflects where you are on the dose schedule. The results these drugs are known for were measured at weeks 68 and 72.
Why the scale is least reliable when you watch it most
On the Wegovy label, semaglutide titration starts at 0.25 mg weekly and steps up about every four weeks: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg, going slower if side effects get in the way. At week 6 you’re on 0.5 mg, which is about a fifth of the dose used in the study.
STEP 1 (Wilding et al., NEJM 2021) studied 1,961 adults with obesity and no diabetes. On brand-name semaglutide (Wegovy) 2.4 mg, they lost 14.9% of their body weight on average, compared with 2.4% on placebo. But that was at week 68. At week 6, you’re judging a dose you aren’t on yet, less than a tenth of the way through the timeline.
The drug’s mechanism adds its own noise. GLP-1 medicines slow gastric emptying (how fast your stomach empties) and act on the appetite centers in your brain. The slower stomach is why nausea was the most common side effect of brand-name semaglutide (Wegovy) in STEP 1. It’s also why nausea clustered during dose increases, and why each dose step can change what you eat for days.
Add in shifts in water, stored carbohydrate (glycogen), salt, and gut contents, and a Tuesday-to-Wednesday reading tells you almost nothing about fat.
The weekly weigh-in, done right
Use the same scale on the same morning each week, after the bathroom and before food or coffee. Log it and compare months instead of weeks. The monthly trend tracks tissue actually lost, while the day-to-day number mostly tracks water moving around. Daily weighing catches that noise at its worst, and it tends to turn it into a bad mood.
The tape and the waistband
Measure your waist once a week at your belly button, after a normal breath out. Keep the tape snug but not digging in, and use the same spot every time.
Waist size is the standard clinical stand-in for visceral fat (the fat around your organs). That comes from guideline consensus. And tape technique wobbles, so consistency matters more than precision.
Check your clothes once a month, using one fixed waistband and one shirt. That’s not a trial measure either, of course, but it’s a slow average of everything else on this list.
Grip strength: the one everyone skips
Not everything you lose on these drugs is fat. In DXA substudies of the GLP-1 trials (body scans that measure fat and lean mass), a real share of the weight lost was lean mass. Whether that costs function long-term, we don’t know yet. But keeping muscle is easier than rebuilding it.
The countermeasure is simple and standard: strength training plus enough protein. A range often cited is 1.2–1.6 g/kg/day, which is about 110–145 g for a 200-lb person, but your clinician can set your own target.
The monthly grip test checks whether it’s working. A $25 hand-grip meter (called a dynamometer) is a crude tool. And grip is a stand-in for strength, since it doesn’t measure lean mass. But grip that holds steady while the scale drops is decent evidence you’re keeping your strength. If your grip slips, fix your protein and training first.
Resting heart rate: expect a small rise
Resting heart rate looks like the obvious smartwatch metric, since fitness usually brings it down. On semaglutide, the safety data point the other way. Resting heart rate rises a few beats per minute on average, and that rise is on the US label. Why it happens isn’t settled.
A small rise in resting heart rate is expected and on the label. The one that matters is the one you can feel. If your heart is pounding or racing while you’re sitting still (not after stairs or coffee), contact us the same day instead of waiting for your next visit. Chest pain, fainting, or almost fainting doesn’t go through us at all. That’s emergency care.
The real heart evidence isn’t on your watch. SELECT (Lincoff et al., NEJM 2023) studied 17,604 adults with overweight or obesity, established cardiovascular disease, and no diabetes. Brand-name semaglutide (Wegovy) 2.4 mg lowered major heart events by 20% in relative terms (HR 0.80). That was proven in people who already had heart disease. Be careful about applying it to anyone else.
Week 12 is a check-in
On the Wegovy label’s schedule, by week 12 you’ve had about four weeks at 1.0 mg, and the full dose arrives around week 17 at the earliest. A good week-12 check asks three questions.
First, do your side effects follow the expected pattern? Nausea that spikes at a dose step and fades between steps is delayed gastric emptying doing what it does. If your nausea isn’t fading, or you’re vomiting so much you can’t keep fluids down, contact your clinician before the next step. At Zappy, a US-licensed clinician reviews every case and sets the pace.
Second, do the numbers agree? Look at the scale trend, the tape, the waistband, and your grip, because the direction matters more than any single reading.
Third, is the dose right? Tirzepatide adds action on a second hormone, GIP, to the GLP-1 effect. In SURMOUNT-1 (Jastreboff et al., NEJM 2022), 2,539 adults took brand-name tirzepatide (Zepbound) for 72 weeks. Higher doses led to more weight loss: 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, compared with 3.1% on placebo. Dose is one lever, and week 12 is a good time to ask your clinician whether yours is right. That doesn’t mean it should go up. Your clinician looks at the whole picture.
Week 12 is not the time to quit because the number looks small. In STEP 4 (Rubino et al., JAMA 2021), people taken off brand-name semaglutide (Wegovy) at week 20 regained a lot of weight, while people who kept going didn’t.
SURMOUNT-4 (Aronne et al., JAMA 2024) is even clearer. After 36 weeks of brand-name tirzepatide (Zepbound), people switched to placebo regained about 14% of their body weight over the next year. Those who stayed on lost about 5.5% more. Staying on the drug keeps the weight off, and stopping without a maintenance plan usually undoes the loss.
The question no trial has answered
The scale, the tape, and the waistband measure mass, but none of them measures what your body can do with it. Here’s the missing trial. Does the lean mass lost on GLP-1s cost real function by year five, and does training plus 1.2–1.6 g/kg/day of protein fully make up for it? Until that trial exists, the $25 grip meter is the closest thing you have. It’s a crude tool pointed at the most important question.
